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Abstract. Drug-transporter interactions could impact renal drug clearance and should
ideally be detected in early stages of drug development to avoid toxicity-related withdrawals
in later stages. This requires reliable and robust assays for which current high-throughput
screenings have, however, poor predictability. Kidney-on-a-chip platforms have the potential
to improve predictability, but often lack compatibility with high-content detection platforms.
Here, we combined conditionally immortalized proximal tubule epithelial cells overexpress-
ing organic anion transporter 1 (ciPTEC-OAT1) with the microﬂuidic titer plate OrganoPlate
to develop a screenings assay for renal drug-transporter interactions. In this platform, apical
localization of F-actin and intracellular tight-junction protein zonula occludens-1 (ZO-1)
indicated appropriate cell polarization. Gene expression levels of the drug transporters
organic anion transporter 1 (OAT1; SLC22A6), organic cation transporter 2 (OCT2;
SLC22A2), P-glycoprotein (P-gp; ABCB1), and multidrug resistance-associated protein 2
and 4 (MRP2/4; ABCC2/4) were similar levels to 2D static cultures. Functionality of the
efﬂux transporters P-gp and MRP2/4 was studied as proof-of-concept for 3D assays using
calcein-AM and 5-chloromethylﬂuorescein-diacetate (CMFDA), respectively. Confocal
imaging demonstrated a 4.4 ± 0.2-fold increase in calcein accumulation upon P-gp inhibition
using PSC833. For MRP2/4, a 3.0 ± 0.2-fold increased accumulation of glutathione-
methylﬂuorescein (GS-MF) was observed upon inhibition with a combination of PSC833,
MK571, and KO143. Semi-quantitative image processing methods for P-gp and MRP2/4 was
demonstrated with corresponding Z′-factors of 0.1 ± 0.3 and 0.4 ± 0.1, respectively. In
conclusion, we demonstrate a 3D microﬂuidic PTEC model valuable for screening of drug-
transporter interactions that further allows multiplexing of endpoint read-outs for drug-
transporter interactions and toxicity.
KEY WORDS: Drug-transporter interaction; Nephrotoxicity; Efﬂux transport; Microﬂuidics; Drug
screening.
INTRODUCTION
Excretion of metabolic waste products and drugs from
blood into the urine takes place in the kidney and is a result
of glomerular ﬁltration, active tubular secretion, and reab-
sorption. It has been estimated that about one third of the
commonly used drugs and compounds tested in clinical trials
are being (partially) removed via the urine without further
metabolism (1,2). Renal clearance thus is a pivotal parameter
to take into account during drug disposition studies in drug
development.
Active tubular secretion of drugs in the kidney takes
place mainly by the proximal tubule epithelial cells (PTEC)
of the nephron and involves transporters (3). Uptake from
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blood to PTEC is mediated by members of the solute carrier
(SLC) transporter family, such as organic cation transporter 2
(OCT2/SLC22A2) and organic anion transporter 1 and 3
(OAT1/SLC22A6; OAT3/SLC22A8). To complete elimina-
tion via urine from compounds internalized via SLC-
mediated transport over the basolateral membrane, a range
of drug transporters is expressed at the apical membrane of
PTEC. This energy-demanding process is facilitated by
transporters classiﬁed in the ATP-binding cassette (ABC)-
transporter family, such as P-glycoprotein (P-gp/ABCB1),
breast cancer resistance protein (BCRP/ABCG2), and multi-
drug resistance-associated proteins 2 and 4 (MRP2/ABCC2;
MRP4/ABCC4). Other drug transporters present at the apical
membrane are the multidrug and toxin extrusion proteins 1
and 2-k (MATE1/SLC47A1; MATE2-k/SLC47A2). In drug
development, investigating interactions with a sub-set of drug
transporters is recommended by the regulatory agencies, such
as the US Food and Drug Administration (FDA) and the
European Medicines Agency (EMA) (4,5). Clinical studies
have shown drug-transporter interactions with, e.g., digoxin,
ritonavir, or valspodar (PSC833), and with tenofovir via P-gp
and MRP2/4, respectively (6–8).
In the past decade, multiple renal immortalized cell lines
have been established, allowing in vitro screening of nephro-
toxicity and renal drug transporters. Conditionally immortal-
ized PTEC (ciPTEC) are derived from a healthy volunteer
and manifest a stable expression and functionality of OCT2,
P-gp, and MRP4 (9). Further transduction resulted in stable
expression and functionality of OAT1 or OAT3 (10). Multiple
studies have shown the potential of ciPTEC for studying drug
transport and drug-induced toxicity cultured under conven-
tional static conditions, often referred to as two-dimensional
(2D) cell culture (10–13). In addition, transepithelial barrier
function, polarization, and transport of cations and anions
have been demonstrated in ciPTEC cultured in a three-
dimensional (3D) model using a tailor-made hollow ﬁber
membrane system exposed to ﬂow (13,14). Beneﬁts of 3D
microﬂuidic models incorporating ﬂuid shear stress (FSS) and
cell-extracellular matrix (ECM) interactions are often re-
ferred to as organ-on-a-chip or microphysiological systems.
Using PTEC, kidney-on-a-chip platforms have been demon-
strated to improve proximal tubule characteristics, such as
increased expression of tight-junction protein zonula
occludens-1 (ZO-1) and increased number of ciliated cells
(15). Kidney-on-a-chip platforms could therefore advance
predictability of large in vitro screenings, also referred to as
high-throughput screening (HTS), which are typically
employed during early phases in drug development.
The current study focuses on implementing a kidney-on-
a-chip platform for the determination of drug-transporter
interactions during drug development. To this end, we culture
human ciPTEC-OAT1 in a microﬂuidic titer plate, the
OrganoPlate, that enables 3D culture under FSS. The
OrganoPlate consists of 40 or 96 chips and is based upon a
384-well microtiter plate format (16,17). Flow is induced by
passive leveling by gravity of medium in medium-channel
inlets and outlets of chips, creating a bi-directional ﬂow. Using
this platform, we assessed stability in drug transporter
expression and functionality via ﬂuorescence-based 3D drug
efﬂux assays to evaluate P-gp and MRP2/4 transporter
activities. In addition, we set up a user-friendly data analysis
method using open-source software compatible with HTS.
This approach resulted in a 3D microﬂuidic PTEC model
suitable for HTS of drug-transporter interactions.
MATERIALS AND METHODS
Cell Culture
CiPTEC-OAT1 were obtained as described previously
(9,10). Brieﬂy, cells were retrieved from urine from a healthy
volunteer in compliance with the guidelines of the Radboud
Institutional Review Board and conditionally immortalized
via transduction with the temperature-sensitive mutant of SV
large T antigen (SV40T) and human telomerase reverse
transcriptase (hTERT) (9). Transduction of OAT1 in ciPTEC
was performed using lentiviral particles containing genes
encoding for human OAT1 (10).
Cells were sub-cultured at a dilution of 1:2 to 1:6 at 33°C and
5% (v/v) CO2 to allow proliferation and were used from passage
numbers 48 to 60 for experiments. Cells were cultured in a 1:1
mixture of Dulbecco’s modiﬁed Eagle’s medium (DMEM) and
Ham’s F-12 nutrient mixture without phenol red (DMEM
HAM’s F12, Life Technologies, Paisley, UK) and supplemented
with insulin (5 μg/ml, Sigma-Aldrich, Zwijndrecht, the Nether-
lands); transferrin (5 μg/ml, Sigma-Aldrich); selenium (5 ng/ml,
Sigma-Aldrich); hydrocortisone (36 ng/ml, Sigma-Aldrich); epi-
dermal growth factor (10 ng/ml, Sigma-Aldrich); tri-iodothyrine
(40 pg/ml, Sigma-Aldrich); 1% (v/v) penicillin/streptomycin (Life
Technologies); and 10% (v/v) fetal calf serum (FCS, Greiner Bio
One, Kremsmuenster, Austria), further referred to as PTEC
complete medium.
For 2D static cell culture, cells were seeded at 55,000
cells/cm2 in 6-well plates and cultured for 1 day at 33°C 5%
(v/v) CO2 without penicillin/streptomycin to allow prolifera-
tion. Then, cells were cultured for 7 days at 37°C 5% (v/v)
CO2 to induce maturation into conﬂuent cell monolayers.
Cells were harvested on day 8 after seeding.
For 3D FSS cell culture, a 400 μm two-lane OrganoPlate
(Mimetas, Leiden, the Netherlands) was used for culturing
ciPTEC-OAT1 in a microﬂuidic platform. Prior to seeding,
50 μl of Hank’s balanced salt solution (HBSS, Life Technol-
ogies) was added to the observation window (Fig. 1a). An
ECM mix containing collagen I (4 mg/ml, AMSbio Cultrex
3D Collagen I Rat Tail); sodium bicarbonate (3.7 mg/ml,
Sigma-Aldrich); and HEPES (100 mM, Life Technologies)
was prepared and 2 μl was added to the gel channel (17).
Then, the OrganoPlate was placed at 37°C 5% (v/v) CO2 for
30 min to allow polymerization of the ECM. Proliferating
cells were harvested from a culture ﬂask using accutase
(Sigma-Aldrich), centrifuged (300×g, 5 min) and then resus-
pended in PTEC complete medium. Per chip, 40,000 cells in a
suspension of 2 μl were seeded in the medium-channel inlet
(Fig. 1a, b). In chips used for background correction of
ﬂuorescent signal, 2 μl of medium was used. The OrganoPlate
was then placed vertically at 33°C 5% (v/v) CO2 for 30 min
with the gel channel facing down to allow cells to attach to the
ECM (Fig. 1b). Next, 30 μl of PTEC complete medium was
added to the medium channel inlet. The OrganoPlate was
oriented horizontally again at 33°C 5% (v/v) CO2 for 4 to 6 h.
Upon addition of another 30-μl PTEC complete medium to
the medium channel inlet, 60-μl PTEC complete medium was
87 Page 2 of 13 The AAPS Journal (2018) 20: 87
added to the medium channel outlet. CiPTEC-OAT1 in the
OrganoPlate was cultured at 33°C 5% (v/v) CO2 to allow
proliferation without any FSS for 3 days. Medium was
supplemented with 1% (v/v) penicillin/streptomycin when
culturing at 33°C.
At day 3 after seeding, medium channels were refreshed
with PTEC complete medium without penicillin/streptomycin
and the OrganoPlate was placed on an interval rocker platform
(angled at − 7° or + 7° from base, 8-min interval) at 37°C 5% (v/v)
CO2 to allow the cells to maturate under FSS induced by a bi-
directional ﬂow (Fig. 1b, c). Experiments in theOrganoPlatewere
performed on day 8 after seeding, unless stated otherwise.
Medium was refreshed every 2 to 3 days.
For long-term cell culture of ciPTEC-OAT1 in the
OrganoPlate, chips were pre-coated (30 min, 37°C) prior to
seeding with L-3,4-dihydroxydiphenylalanine (L-DOPA,
2 mg/ml in 10 mM Tris pH 8.5, Sigma-Aldrich) as earlier
described (18). Cells were then cultured at 33°C on an
interval rocker, as above described, for 20 days.
Immunoﬂuorescence staining of ciPTEC-OAT1 in the
OrganoPlate
At days 8 and 20 after seeding, PTEC completemediumwas
aspirated from the medium channel and cells were ﬁxated with
3.7% (w/v) formaldehyde (Sigma-Aldrich) in HBSS. The plate
Fig. 1. Overview of two-lane OrganoPlate and cell culture, assay and image analysis protocol. a
Schematic overview of a two-lane OrganoPlate consisting of a gel channel (red) and medium
channel (blue) and covering four wells of a 384-wells plate. Four wells are named 1 = gel channel
inlet, 2 = medium channel inlet, 3 = observation window. and 4 = medium channel outlet. Dotted
line indicates position of cross-sectional overview (b). b Cross-sectional overview of culture
protocol of ciPTEC-OAT1 in the OrganoPlate: 1 = addition of ECM to the gel channel creating
two membrane-free compartments because of the phaseguide; 2 = seeding of ciPTEC-OAT1; 3 =
by placing the plate vertically, cells are allowed to attach to ECM by gravity; 4 = ciPTEC-OAT1 is
allowed to mature under FSS; 5 = two compartments are created per chip consisting of an
extracellular matrix (ECM) and an apical channel (medium channel). c Culture conditions and
assay details of 3D P-gp, MRP2/4 drug efﬂux assay speciﬁed. Image analysis in Fiji contained
background correction, image QC (visual observation) and normalization. Z stacks per chip were
acquired using 10-μm intervals between each Z stack resulting in a total number of ﬁve Z stacks
per chip. Cells on ECM and medium interface were selected for further analysis and calculation
of the average intensity of Z stacks per chip
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was incubated for 15 min at room temperature. For all described
incubation and wash steps, 50 μl was added to the inlet and outlet
of the medium channel, and plate was placed at angle to allow
perfusion, unless stated otherwise. Fixative was aspirated and
medium channels were washed twice with washing solution (4%
(v/v) FCS in HBSS). Then, cells were permeabilized by adding
0.3% (v/v) Triton-X100 (Sigma-Aldrich) in HBSS and incubated
for 10 min at room temperature. Cells were subsequently washed
with washing solution and then incubated with blocking solution
(2% (v/v) FCS, 2% (w/v) bovine serum albumin (BSA, Sigma-
Aldrich), 0.1% (v/v) Tween-20 (Sigma-Aldrich) in HBSS) for
45 min at room temperature. Primary and secondary antibodies
were diluted in blocking solution and perfusion during incubation
was allowed by adding 30 μl to themedium channel inlet and 10 μl
to the outlet. Primary antibodies against zonula occludens-1 (ZO-
1, 1:125, rabbit, Thermo Fisher), a tight-junction protein;
acetylated-tubulin (clone 6-11B-1, 1:1000,mouse, Sigma-Aldrich),
a constituent of the primary cilium; and pericentrin (1:500, rabbit,
Abcam), a centrosome marker, were used and incubated for
60 min at room temperature. Next, cells were washed three times
with washing solution and then incubated with secondary
antibodies Alexa Fluor® 488 goat anti-rabbit (1:250, Life
Technologies or Abcam), Alexa Fluor® 488 goat anti-mouse
(1:250, Life Technologies), andAlexa Fluor® 647 goat anti-rabbit
(1:250, Life Technologies) for 30 min at room temperature. Cells
were then washed three times, followed by addition of probes in
the last wash step to stain F-actin and nuclei with ActinRed 555
(two drops per milliliter in HBSS, Life Technologies) and
DRAQ5 (1:1000 in HBSS, Abcam) or DAPI (300 nM in HBSS,
Life Technologies), respectively. Fluorescent images of the ZO-1
staining were acquired with a Leica TCS SP5 laser point confocal
microscope (Leica, Wetzlar, Germany) or a Zeiss LSM880
confocal scanning microscope (Carl Zeiss, Jena, Germany) using
a ×20 objective.Z stacks were acquired using a 2 μm interval over
a 200–220 μm range. To investigate polarization of the PTEC
monolayer of ciPTEC-OAT1 in the OrganoPlate, ﬂuorescent
images were acquired of acetylated-tubulin and pericentrin
staining with a Zeiss LSM880 confocal scanningmicroscope using
a ×40 water immersion objective. A range of 45 μm was imaged
using a 0.88-μm interval between Z stacks. Images were adjusted
for windows and level, and then 3D images were reconstructed in
Fiji (version 1.51n) (19).
Gene Expression of ciPTEC-OAT1
Cells were harvested from 6-well plates using Accutase,
and then RNA was extracted using the RNeasy Mini kit
(QIAGEN, Venlo, the Netherlands). RLT lysis buffer was
added to the cell pellet and RNA was then extracted
according to the protocol provided by the manufacturer.
RNA from cells in the OrganoPlate was isolated using
the RNeasy Micro kit (QIAGEN). From each chip, RNAwas
isolated by adding 50 and 25 μl RLT lysis buffer to the
medium channel inlet and outlet, respectively. Cell lysates of
two chips were then pooled and RLT lysis buffer was added
up to a volume of 350 μl. The extracted RNA was puriﬁed
following the manufacturer’s protocol.
M-MLV reverse transcriptase (Promega, Madison, USA)
was used to synthesize complementary DNA (cDNA) according
the manufacturer’s protocol. Human kidney cortex material was
used as reference. Tissues unsuitable for transplantation were
obtained for research purposes from three donors, who gave
permission and which was registered in the DutchDonor registry.
RNA isolation and cDNA synthesis were performed as previ-
ously described (20). The expression levels of mRNA were
quantiﬁed using gene-speciﬁc primer-probe sets from Applied
Biosystems (Bleiswijk, the Netherlands): GAPDH
(hs99999905_m1), HPRT1 (hs02800695_m1), SLC22A6
(hs00537914_m1), ABCB (hs01067802_m1), ABCC2
(hs00166123_m1), ABCC4 (hs00195260_m1), SLC22A2
(hs01010723_m1), and TaqMan Universal polymerase chain
reaction (PCR) Master Mix. Quantitative PCR reactions were
carried out using CFX96-Touch Real-Time PCR System
(BioRad, Veenendaal, the Netherlands) and analyzed with
BioRad CFX Manager (version 3.1). Expression levels of
GAPDH were used as reference gene.
3D Drug Efﬂux Assays in the OrganoPlate
Functionality of P-gp and MRP2/4 was assessed based
upon accumulation of substrates, as previously described for
ciPTEC in 2D (Fig. 1c) (12). Prior to measuring efﬂux activity
of P-gp and MRP2/4 in the OrganoPlate, medium-channel
inlet and outlets were washed with 50 μl KHH at 37°C.
Medium channels were then perfused two times. Then, cells
were exposed to substrates with or without inhibitors or
corresponding vehicle for 1 h at 37°C.
For P-gp activity assessments, calcein-AM (2 μM, Life
Technologies) was used as substrate and PSC833 (10 μM,
Tocris, Bristol, UK) was used as inhibitor. Calcein-AM and
PSC833 were dissolved in DMSO (Sigma-Aldrich). All
dilutions were prepared in Krebs-Henseleit buffer (Sigma-
Aldrich) supplemented with HEPES (10 mM, Sigma-Aldrich)
and adjusted to pH 7.4 (KHH).
Chloromethylﬂuorescein-diacetate (CMFDA, 1.25 μM,
Molecular Probes) was used to study MRP2/4 activity. A
combination of PSC833 (10 μM); KO143 (10 μM, Sigma-
Aldrich); and MK571 (10 μM, Sigma-Aldrich) was used to
inhibit efﬂux of CMFDA and glutathione-methylﬂuorescein
(GS-MF) via P-gp, BCRP, and MRP2/4, respectively.
CMFDA and KO143 were dissolved in DMSO, while
MK571 was dissolved in Milli-Q water, requiring appropriate
vehicle controls. All dilutions were prepared in KHH.
After substrate incubations, cell nuclei were stained with
Hoechst33342 by ﬁrst washing with KHH, followed by
staining with Hoechst33342 (10 μg/ml, Molecular Probes)
for 10 min at room temperature. Cells were co-incubated with
PSC833 (10 μM), KO143 (10 μM), and MK571 (10 μM)
during staining with Hoechst33342 to inhibit all efﬂux
transport processes. Subsequently, cells were washed and
efﬂux of calcein-AM and GS-MF was arrested by adding ice-
cold KHH to medium channel. FSS in medium channel
during experiment and washing was assured by adding 80 μl
to the medium channel inlet and 20 μl to the medium channel
outlet.
Fluorescent Imaging in the OrganoPlate
Fluorescence of intracellular accumulation of calcein or
GS-MF and Hoechst33342 in ciPTEC-OAT1 cultured in the
OrganoPlate were imaged in situ using a Becton Dickinson
(BD) Pathway 855 high-throughput microscope (BD
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Bioscience, Breda, The Netherlands) using a ×10 objective
(Fig. 1c). The BD Pathway 855 microscope was compatible
with the two-lane OrganoPlate and allowed to acquire images
of the observation window of each chip using two different
ﬂuorescent dyes with wild-ﬁeld microscopy and spinning disk
confocal microscopy at room temperature. A macro was
developed to acquire ﬂuorescent and bright-ﬁeld images using
BD AttoVision (version 1.6, BD Bioscience). Z height was
determined per experiment by determining the top and
bottom of multiple chips in the OrganoPlate visually. The
average height was used as starting point for acquiring ﬁve Z
planes with a 10 μm interval, covering 50 μm in Z direction,
generating focused images of cells cultured against ECM.
First, calcein and GS-MF ﬂuorescence images were acquired
(488-nm excitation and 520-nm emission ﬁlters) with expo-
sure time and gain set at 0.5 s and 100, respectively.
Hoechst33342 images were acquired subsequently (360-nm
excitation ﬁlter and 435-nm emission ﬁlter), with exposure
time and gain set at 0.01 s and 100, respectively. Afterwards,
bright-ﬁeld images of each chip were acquired using an
exposure time of 0.02 s.
Image Processing
An image analysis method (Fig. 1c) was set up to analyze
the full data set using custom made macros in Fiji. Initially,
the region of interest (ROI) was selected from bright-ﬁeld
images in which the gel channel, medium channel and the
phase guide were clearly visible, by focusing at the interface
of ECM and medium. The same area size was used for all
images. All raw ﬂuorescence images (uncompressed 12-bit
TIFF) were cropped based upon the interface selection and
converted from a pixel to micrometer scale. Then, the raw
ﬂuorescence images were corrected for background noise by
subtracting images of chips with ECM without any cells
exposed to either calcein-AM or CMFDA. Background-
corrected images were saved to an uncompressed 16-bit TIFF
ﬁle and the average intensity was calculated (see macro in
Supplementary Material). In parallel, a mask was created for
each image using 17 threshold algorithms available in Fiji
(Table S1 in Supplementary Material) to automatically
determine localization of intracellular accumulated ﬂuores-
cent calcein or GS-MF. Upon running a median image ﬁlter
(radius size ﬁve pixels), a cell selection mask was created via
the selected algorithm to create a binary image. Pixels from
the edges of the cell selection mask in the binary image were
removed using Berode^ in Fiji. The binary image represented
a cell selection and was used to analyze ﬂuorescence intensity
of each Z stack per chip.
As part of the image quality control (QC), only in-focus
images of cells cultured at the ECM and medium interface
were selected and reviewed by three independent observers
(Fig. 1c). An image was deﬁned as out-of-focus if no in-focus
cell in the ROI were scored by at least two of the three
observers.
Manual interventions, such as determination of out-of-
focus images are not compatible with HTS. Therefore,
selected image QC metrics were established to automatically
exclude out-of-focus images: focus score, image correlation,
and power log-log slope (PLLS), which all have been
described in literature for image analysis (21–24). An image
QC method was set up using these image QC metrics in
CellProﬁler (version 2.2.0) (25,26). For the focus score, the
deviation of pixel intensity was assessed upon normalization
per image. The correlation of the grayscale value of
neighboring pixel was evaluated for image correlation. Pixel
size for image correlation and focus score was empirically
based upon the area of the observed intracellular accumula-
tion of calcein or GS-MF and set at 20, 50, 100, 200, and 500
pixels. For the PLLS, the slope of power spectral density
versus the spatial frequency, both on a log scale, was plotted.
All images were automatically binned based upon the image
QC metrics in GraphPad Prism (version 5.03). Multiple cutoff
values were compared per image QC metric. The efﬁciency of
the automated image QC metrics was compared to visually
reviewing of out-of-focus scoring as described earlier, which
was deﬁned as ground truth. For all image QC metrics, the
precision and recall rates were determined, as well as the
harmonic mean of the precision and recall rates, also known
as F score. Precision, recall, and F score were calculated as
follows:
F score ¼ 2 precision recall
precisionþ recall
where precision is:
precision ¼ true positives
true positivesþ false positives
and recall is:
recall ¼ true positives
true positivesþ false negatives
Average intensities of visual observation in-focus im-
ages were calculated per chip (Fig. 1c). Two to eight chips
were analyzed per condition and repeated in at least three
independent experiments. All groups were checked for
outliers using Grubbs’ test for outliers (using a signiﬁcance
level of α = 0.05) and ﬁnally normalized to average ﬂuores-
cence intensity in vehicle condition per experiment.
The Z′ factor was used to index the thresholding
algorithms and overall intensity per image and condition to
assess quality and optimize the data analysis methods. The Z
′-factor has been described as statistical parameter in HTS
assays taking in account the variation between a signal in
maximum response, the positive control, and minimum
response, the negative control (27). Hence, the Z′ factor can
be used as guideline to optimize semi-quantitative methods in
order to improve discrimination between the positive and
negative controls. Mean and standard deviation (SD) were
determined for the positive control, inhibitor condition, and
negative control, vehicle condition, to calculate the Z′ factor
per experiment as follows:
Z
0
factor ¼ 1− 3 σ positive controlþ σ negative controlð Þ
μ positive control−μ negative controlj j
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Statistical Data Analysis
All statistics were performed using GraphPad Prism.
Data is presented as mean ± SEM of at least three indepen-
dent experiments (n = 3) and considered to be signiﬁcantly
different if p < 0.05 using an unpaired two-tailed Student’s t
test, unless stated otherwise.
RESULTS
PTEC’s Formed a 3D Tubular Structure in the OrganoPlate
Upon seeding ciPTEC-OAT1 against the ECM in the
two-lane OrganoPlate, cells formed a monolayer that mi-
grated towards the top and bottom of the medium channel,
creating a tubule-like structure at day 8 after seeding (Fig. 2a,
Fig. S1). PTEC tubules could be cultured up to 20 days in the
OrganoPlate (Fig. S2). ZO-1, a tight-junction protein, was
localized between the cells in the monolayer of the PTEC
tubules (Fig. 2b), indicative for polarization. Staining of the
centrosome, or pericentrin, and acetylated-tubulin, showed
apical expression of single cilia per cell (Fig. 2c; Fig. S3).
Some migration of ciPTEC-OAT1 from the medium channel
into the ECM was observed, likely inﬂuencing the monolayer
integrity. Although the majority of cilia were mainly
expressed at the apical side of the tubules, some cilia were
observed on single cells that migrated into the ECM (Fig. S3).
Drug Transporter Gene Expression in ciPTEC-OAT1 Cul-
tured in the OrganoPlate
Drug transporter gene expression levels in ciPEC-OAT1
cultured in 2D static (6-well plate) and under FSS (OrganoPlate)
were compared (Fig. 3). Expression levels of SLC transporters
Fig. 2. Immunoﬂuorescence staining of ciPTEC-OAT1 in OrganoPlate. a Three-dimensional (3D)
view of ciPTEC-OAT1 in OrganoPlate with F-actin (red) and nuclei (DAPI, blue) showing the
formation of tubule structures after 8 days of seeding. The phase guide is visible as blue bar at the
left side of the image. The lumen at the apical side and the extracellular matrix (ECM) are
indicated. Scale bar represents 100 μm. b Staining of nuclei (DAPI, blue) and zonula occludens
(ZO-1, green). Expression of ZO-1 visible between cell monolayer on top of PTEC tubules. Scale
bar represents 100 μm. c Representative images of single cells attached to the extracellular matrix
(ECM) selected from the tubular ciPTECOAT1 structures in the OrganoPlate, showing staining of
nuclei (DAPI, blue) and primary cilia with pericentrin (magenta) and acetylated tubulin (green).
Most cilia face towards the lumen (apical side), demonstrating polarization of the tubules. Scale
bar represents 20 μm
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OAT1 and OCT2 and ABC transporters P-gp and MRP2/4 were
found to be similar in ciPTEC-OAT1 cultured in theOrganoPlate
as compared to 2D cultures. This indicates a maintained
phenotype of ciPTEC-OAT1 when cultured in the OrganoPlate.
Only expression levels of HPRT1, here assessed to be used as a
reference gene, were lower in ciPTEC-OAT1 cultured in the
OrganoPlate and, consequently, not valid as reference gene. On
the other hand, reference gene GAPDH was stably expressed in
ciPTEC-OAT1 cultured both in 6-well plate and in the
OrganoPlate® with corresponding Ct values of 19.7 ± 0.1 and
19.6 ± 0.1, respectively. It is important to note that drug
transporter gene expression levels presented here were derived
from cells both located in the perfused channels, as well as the
medium channel inlet and outlets. As the latter cells are not
exposed to laminar ﬂow, norwere cultured in 3D, gene expression
proﬁling was based on a hybrid population and should be
regarded as qualitative measurement.
In addition, expression levels of ciPTEC-OAT1 cultured in
6-well plate or in the OrganoPlate® were compared to expression
levels in human kidney cortex samples (Table I). In human kidney
cortex, OAT1 ismost abundantly expressed relative to expression
levels of other drug transporters assessed here (rank order OAT1
>MRP2 >MRP4 >OCT2 > P-gp). Expression of OAT1was also
abundantly expressed in ciPTEC-OAT1when cultured either in a
6-well plate or in the OrganoPlate, although a different relative
expression was observed (rank order OAT1 > MRP4 > P-gp >
MRP2 > OCT2).
Fluorescence-based Drug Efﬂux Assays in 3D Tubule
Structures
We set up 3D efﬂux assays for P-gp and MRP2/4 as
proof-of-concept to demonstrate transport activity in 3D
microﬂuidic PTEC model. The ﬁrst step in our image analysis
included the selection of the ROI per chip, which included
cells at the ECM and medium interface. As shown in Fig. 4a,
the gel channel, medium channel, and the phase guide were
clearly visible. The bright-ﬁeld images were used to objec-
tively choose the ROI per chip. Cell layers formed at the
ECM were demonstrated by the Hoechst staining (Fig. 4a).
P-gp shows the highest afﬁnity for uncharged and
positively charged compounds (28,29). Calcein-AM was used
as substrate to study P-gp efﬂux activity in ciPTEC-OAT1
cultured in the OrganoPlate. Calcein-AM can freely diffuse
through the cell membrane and is a substrate with high
afﬁnity for P-gp. Intracellular, calcein-AM is metabolized
through esterase activity into the ﬂuorescent calcein. Slight
accumulation of calcein was observed in the control and
vehicle incubated tubules upon incubation with calcein-AM
(Fig. 4a), which was strongly enhanced upon co-incubation
with PSC833, suggesting inhibition of P-gp (Figs. 4a and 5a).
MRP2/4 show highest afﬁnity for negatively charged
compounds in the kidney (30–33). To study MRP2/4 activity,
5-chloromethylﬂuorescein-diacetate (CMFDA), which enters
the cell via diffusion, was used. CMFDA is then metabolized
to the ﬂuorescent 5-chloromethylﬂuorescein (CMF) via
esterase activity and then further metabolized into
carboxylﬂuorescein-glutathione (GS-MF) through direct in-
teraction with glutathione (GSH) or via transferase activity.
CMF is completely transferred into GS-MF during incubation
time used here (12). GS-MF is predominantly a substrate for
Fig. 3. The HPRT1, OAT1, OCT2, P-gp, MRP2, and MRP4
expression levels in matured ciPTEC-OAT1 cultured under FSS
(OrganoPlate). Gene expression levels were normalized to GAPDH,
used as reference gene, and here calculated a fold difference
compared to gene expression levels in 2D static cell culture (6-well
plate). **p < 0.01 compared to mRNA expression in ciPTEC-OAT1
cultured in a 6-well plate
Table I. mRNA expression in human kidney cortex and ciPTEC-OAT1 cultured in 2D static or in the OrganoPlate
ΔCt Relative expression ciPTEC-OAT1 vs. hKidney
hKidney ciPTEC-OAT1
6-well OrganoPlate 6-well (%) OrganoPlate (%)
HPRT1 4.2 ± 0.2 6.1 ± 0.1 6.9 ± 0.1 27.6 15.8
OAT1 − 0.7 ± 0.5 2.2 ± 0.2 3.1 ± 0.7 11.5 7.4
OCT2 4.8 ± 0.3 17.5 ± 0.6 17.8 ± 0.3 0.017 0.012
P-gp 4.8 ± 0.5 7.6 ± 0.1 8.9 ± 0.7 12.9 6.3
MRP2 3.0 ± 0.6 14.18 ± 0.04 14.0 ± 0.1 0.037 0.043
MRP4 3.7 ± 0.1 6.3 ± 0.1 6.6 ± 0.4 17.0 14.2
mRNA expression of drug transporters of three independent experiment performed at least in duplicate. Gene expression levels were
normalized to GAPDH, used as reference gene. Ct values of GAPDH in human kidney (hKidney), ciPTEC-OAT1 in 6-well and in the
OrganoPlate were 25.6 ± 0.7, 19.7 ± 0.1, and 19.6 ± 0.1, respectively
ciPTEC conditionally immortalized proximal tubule epithelial cells, OAT organic anion transporter, OCT organic cation transporter, P-gp P-
glycoprotein, MRP multidrug resistance-associated protein
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MRP2/4, although some selectivity was demonstrated for
BCRP and P-gp (12). We therefore used a combination of
inhibitors, as described in the BMaterials and Methods^
section. In the control and vehicle tubules, minor accumula-
tion of GS-MF was visible. After co-incubation with an
inhibitor cocktail of PSC833, KO143, and MK571, a higher
ﬂuorescence intensity was demonstrated as compared to
vehicle control, indicating active MRP2/4 in ciPTEC-OAT1
cultured in the OrganoPlate. Signal intensity was stable for at
least 25 min for both calcein and GS-MF (data not shown).
Image QC and Image Analysis
Setting up a proper image QC could reduce the variation
caused by factors such as out-of-focus images, signal-to-noise
ratio, and cell density. In-focus images of the cell layer
between ECM and medium interfaces were acquired in the
majority of chips. Available image QC metrics in CellProﬁler
were applied to obtain an automated and fast image QC of
our data set.
Each image was visually evaluated to be in-focus or out-
of-focus. Of all images acquired for the 3D P-gp drug efﬂux
assay (n = 245, from four different experiments), 14.3% (n =
35) were assigned to be out-of-focus. For the 3D MRP2/4
drug efﬂux assay, 21.7% (n = 52) of all images (n = 240, from
four different experiments) were assigned to be out-of-focus.
The visually evaluated in-focus and out-of-focus images were
deﬁned as ground truth.
Means of image QC metrics of in-focus and out-of-focus
images were compared for the two transporter assays as
deﬁned for P-gp (Table S2 in Supplementary Material) and
MRP2/4 (Table S3 in Supplementary Material). By calculat-
ing the F score per image QC metric, the false negatives, true
and false positives were incorporated and compared with the
Fig. 4. Representative bright-ﬁeld and ﬂuorescent images of Hoechst and calcein or GS-MF. A cell monolayer is
formed at the phase guide is clearly visible in the center of the bright-ﬁeld images. The ECM and medium
channel are positioned above and below the phase guide, respectively. Hoechst staining was used to improve cell
monolayer visibility. a Accumulation of calcein was visible in control, vehicle, and PSC833-treated tubules.
Accumulation of calcein was increased upon PSC833-mediated inhibition of P-gp. b Intracellular accumulation
of GS-MF in control, vehicle, treated, and in presence of inhibitor cocktail (consisting of PSC833, KO143 and
MK571). Accumulation of GS-MF was increased upon incubation with the cocktail. For visualization, gray
values for bright-ﬁeld, Hoechst, calcein, and GS-MF images were set from 250 to 1000, 0 to 500, 0 to 2000, and 0
to 500, respectively. Gray scale of calcein and GS-MF ﬂuorescent images were converted to look-up table (LUT)
color ﬁre to enhance contrast. Calibration bar of LUT shows level of intensity of calcein or GS-MF. Scale bar in
bright-ﬁeld images represents 100 μm. See Fig. 5 for quantiﬁcation of the signals
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ground truth. Focus score showed an F score of 0.46, the
highest F score of all image QC metrics determined for the
3D P-gp drug efﬂux assay, the recall and precision score
obtained were 0.33 and 0.77, respectively (Table S2 in
Supplementary Material). For the 3D MRP2/4 drug efﬂux
assay, using focus score with a pixel size 200 resulted in an F
score of 0.53, the highest F score for this assay, with
corresponding precision and recall scores of 0.36 and 0.94,
respectively (Table S3 in Supplementary Material). For both
assays, low precision scores were obtained, because of a high
number of false positives compared to true positives, leading
to low F scores.
To demonstrate proof-of-concept, further analysis was
based on the visually determined out-of-focus images by three
observers, since the image QC metrics determined here were
less optimal to distinguish in-focus and out-of-focus images
for our data set. Visually reviewed out-of-focus images were
excluded from further calculations from this point.
Fluorescence Intensity in Image and Average per Chip
Fluorescence intensities per image were determined in
Fiji to perform semi-quantitative analysis of P-gp and MRP2/
4 drug efﬂux activities (Tables II and III). Masking using
thresholding algorithms was applied to create a selection area
incorporating the intracellular accumulation of calcein or GS-
MF and compared to the intensity of the entire image. A
higher intensity after co-incubation with inhibitor(s) was
observed for all semi-quantitative methods used in both drug
efﬂux assays (Tables II and III). No differences between
vehicle-treated and control were observed in the drug efﬂux
assays.
Z′ factor was calculated per experiment to compare and
optimize the semi-quantitative analysis methods.
Thresholding algorithm and the intensity of the entire image
were compared in Tables II and III. Z′ factors are only
meaningful when they fall within a range of − 1 <Z′≤ 1,
which is the case for the majority of the thresholding
algorithms (27). Remarkably, when using algorithm threshold
moments for the 3D P-gp drug efﬂux assay, the mean of the
negative control (vehicle treatment) was higher than the
mean of positive control (PSC833) treatment the in two
experiments, resulting in Z′ > 1. Without using a thresholding
algorithm, this resulted in Z′ factor values of 0.1 ± 0.3 and 0.4
± 0.1 for the 3D P-gp and MRP2/4 drug efﬂux assays,
respectively. For all analysis methods, a signiﬁcant increase
in ﬂuorescence intensity was found upon transport inhibition
for both assays; however, thresholding algorithms resulted in
large standard deviations. In general, Z′ factor values were <
0 when using a thresholding algorithm, because of an overlap
in ﬂuorescence intensity between the groups, indicating that
image analysis using threshold algorithms as presented here is
not suitable for HTS (27). Thresholding algorithms included
more steps in the semi-quantitative analysis macro in Fiji (see
Supplementary Material), which increased the processing
time per image, and Z′ factors were lower compared to the
intensity of the entire image. Therefore, measuring intensity
in the entire image showed the most reliable results.
Upon establishing a valid semi-quantitative image anal-
ysis method for both assays, the average ﬂuorescence
intensities per chip were calculated, as shown in Fig. 5.
PSC833-mediated inhibition of P-gp resulted in a 4.4 ± 0.2-
fold increase ﬂuorescence intensity compared to vehicle
treated tubules (Fig. 5a). For the 3D MRP2/4 drug efﬂux
assay, in tubules co-incubated with PSC833, KO143, and
MK571 led to a 3.0 ± 0.2-fold increased compared to vehicle
(Fig. 5b). Both assays demonstrate function of P-gp and
MRP2/4 and the possibility to semi-quantify renal drug
interaction via increased ﬂuorescence intensity.
DISCUSSION
In this study, we developed a 3D microﬂuidic PTEC
model demonstrated to be suitable for the evaluation of renal
drug interactions with efﬂux transporters. The system has
high potential for early drug screening due to its medium to
high-throughput features and compatibility with high-content
imaging platforms, as shown in the current study on 3D efﬂux
assays as well as demonstrated by Vormann et al.(under
revision at AAPSJ) and Suter-Dick et al. (accepted by
AAPSJ). We cultured the human conditionally immortalized
cell line ciPTEC-OAT1 in the OrganoPlate exposed to FSS
Fig. 5. Average intensity measured per condition and chip is shown for control, solvent-treated and inhibitor-treated
conditions. a Fold difference in calcein or in b GS-MF ﬂuorescence. Values were normalized to vehicle per experiment. No
threshold algorithm was used. Signiﬁcant differences of the means were compared to vehicle using one-way ANOVA
followed by Dunnett’s multi comparison post hoc test. ***p < 0.001 compared to vehicle
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induced by leveling, creating a 3D microﬂuidic PTEC model.
The OrganoPlate enabled the formation of polarized tubule-
like structures in a 96-well format.
A polarized epithelium was obtained upon culturing of
ciPTEC-OAT1 in the OrganoPlate and showed apical expres-
sion of cilia, in line with an earlier publication of a perfusable
printed 3D PTEC (34). Furthermore, gene expression levels
of OAT1 (SLC22A6), OCT2 (SLC22A2), P-gp (ABCB1),
MRP2 (ABCC2), and MRP4 (ABCC4) were conﬁrmed.
Representative monolayers were formed and functional
activity and drug interactions for P-gp and MRP2/4 was
demonstrated by means of ﬂuorescence-based transport
Table II. Fold difference in ﬂuorescence intensity for the 3D P-gp drug efﬂux assay compared to vehicle using different threshold algorithm
available in Fiji and corresponding calculated Z′ factors
Calcein-AMa Calcein-AM + vehiclea Calcein-AM + PSC833a Z′ factorb
No threshold 1.0 ± 0.1 1.0 ± 0.1 4.4 ± 0.2*** 0.1 ± 0.3
Default 0.5 ± 0.1 1.0 ± 0.1 5.3 ± 0.6*** − 2 ± 1
Huang 0.5 ± 0.1 1.0 ± 0.1 4.4 ± 0.5*** − 0.5 ± 0.2
IJ_IsoData 0.5 ± 0.1 1.0 ± 0.1 4.8 ± 0.6*** − 2 ± 1
Intermodes 0.6 ± 0.1 1.0 ± 0.1 4.7 ± 0.7*** − 2 ± 1
IsoData 0.5 ± 0.1 1.0 ± 0.1 5.1 ± 0.6*** − 2 ± 1
Li 0.6 ± 0.1 1.0 ± 0.1 4.4 ± 0.5*** − 0.2 ± 0.3
MaxEntropy 0.6 ± 0.1 1.0 ± 0.1 4.1 ± 0.5*** − 1 ± 1
Mean 0.8 ± 0.1 1.0 ± 0.1 5.0 ± 0.4*** − 0.1 ± 0.3
MinError 0.5 ± 0.1 1.0 ± 0.1 4.8 ± 0.6*** − 2 ± 1
Minimum 0.6 ± 0.1 1.0 ± 0.1 4.6 ± 0.7*** − 2 ± 1
Moments 0.8 ± 0.1 1.0 ± 0.1 3.5 ± 0.6*** 3 ± 2
Otsu 0.5 ± 0.1 1.0 ± 0.1 5.0 ± 0.6*** − 0.1 ± 0.4
Percentile 0.7 ± 0.1 1.0 ± 0.1 3.6 ± 0.5*** − 0.5 ± 0.6
RenyiEntropy 0.6 ± 0.1 1.0 ± 0.1 4.0 ± 0.5*** − 1 ± 1
Shanbhag 0.6 ± 0.1 1.0 ± 0.1 4.6 ± 0.7*** − 2 ± 1
Triangle 0.7 ± 0.1 1.0 ± 0.1 4.0 ± 0.4*** − 2 ± 1
***p < 0.01 compared to vehicle
aValues were normalized to vehicle per experiment. Signiﬁcant differences of the means were compared to vehicle using one-way ANOVA
followed by Dunnett’s multi comparison post hoc test
bAverage Z′ factor as calculated in four independent experiments
Table III. Fold difference in ﬂuorescence intensity for the 3D MRP2/4 drug efﬂux assay compared to vehicle using different threshold
algorithm available in Fiji and corresponding calculated Z′ factors
CMFDAa CMFDA + vehiclea CMFDA + PSC833, KO143, MK571a Z′ factorb
No threshold 1.3 ± 0.1 1.00 ± 0.05 3.0 ± 0.2*** 0.4 ± 0.1
Default 1.3 ± 0.2 1.0 ± 0.1 5.1 ± 0.7*** − 0.4 ± 0.2
Huang 1.2 ± 0.2 1.0 ± 0.1 3.9 ± 0.5*** − 0.6 ± 0.1
IJ_IsoData 1.3 ± 0.2 1.0 ± 0.1 4.2 ± 0.6*** − 0.70 ± 0.05
Intermodes 1.2 ± 0.1 1.0 ± 0.1 3.7 ± 0.3*** − 0.4 ± 0.2
IsoData 1.3 ± 0.2 1.0 ± 0.1 4.6 ± 0.6*** − 0.5 ± 0.2
Li 1.3 ± 0.2 1.00 ± 0.05 4.0 ± 0.4*** − 0.7 ± 0.2
MaxEntropy 1.2 ± 0.1 1.0 ± 0.1 3.7 ± 0.4*** − 0.3 ± 0.3
Mean 1.4 ± 0.2 1.0 ± 0.1 3.4 ± 0.3*** − 0.4 ± 0.4
MinError 1.3 ± 0.2 1.0 ± 0.1 4.2 ± 0.6*** − 0.70 ± 0.05
Minimum 0.9 ± 0.2 1.0 ± 0.1 3.7 ± 0.3*** − 0.2 ± 0.1
Moments 1.2 ± 0.2 1.0 ± 0.1 4.1 ± 0.5*** − 0.3 ± 0.3
Otsu 1.3 ± 0.2 1.00 ± 0.04 4.5 ± 0.6*** − 0.5 ± 0.1
Percentile 1.6 ± 0.3 1.0 ± 0.1 2.9 ± 0.3*** − 1.4 ± 0.2
RenyiEntropy 1.2 ± 0.1 1.0 ± 0.1 3.6 ± 0.3*** − 0.3 ± 0.2
Shanbhag 0.8 ± 0.2 1.0 ± 0.1 4.0 ± 0.7*** − 5 ± 5
Triangle 1.4 ± 0.2 1.0 ± 0.04 3.2 ± 0.2*** − 0.2 ± 0.1
CMFDA chloromethylﬂuorescein-diacetate
***p < 0.01 compared to vehicle
aValues were normalized to vehicle per plate. Signiﬁcant differences of the means were compared to vehicle using one-way ANOVA followed
by Dunnett’s multi comparison post-hoc test
bAverage Z′ factor as calculated in four independent experiments
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assays. Open-source imaging software was used to analyze
ﬂuorescence to make this platform user-friendly and suitable
for screening of larger data sets.
Basal PTEC characteristics were shown to be improved
in kidney-on-a-chip platforms, likely because of inclusion of a
physiological FSS and cell- ECM interaction (15,34,35).
Interestingly, enhanced P-gp efﬂux activity and transepithelial
transport of para-aminohippurate (PAH) was demonstrated
(15,36). Microﬂuidic kidney models could advance lead
optimization at early stages of drug development and are an
emerging technology to study drug-transporter interactions
and toxicity (37). Future efforts demonstrating the improve-
ments of such microﬂuidic 3D PTEC models as compared to
regular 2D static culture should include a validation study
with a compound library focusing on sensitivity and speciﬁcity
using nephrotoxic and non-nephrotoxic compounds. Com-
plexity and lack of compatibility with HTS of current kidney-
on-a-chip models are a major drawback as opposed to 2D
static cell culture in a multiwell setting required for drug
screening purposes. Most published kidney-on-a-chip models
use complex pump-driven single chip systems that frustrate
experiments relying on multiple test conditions (15,34,36,38–
40). The 3D microﬂuidic PTEC model presented here
consisted of 96 chips on one plate and physiological FSS that
is induced by leveling, without the need for external
components. Therefore, it has high potential for HTS settings
and could relatively easily be implemented in current
disposition studies in drug development.
In vitro toxicity screening at early phases of drug
discovery beneﬁts from its compatibility for HTS and low
costs. Freshly isolated human primary PTEC are the golden
standard for in vitro screenings when it comes to intact drug
transporter functionality and resemblance to the human
kidney. However, expression levels decrease within days after
seeding and such studies are limited for their low reproduc-
ibility (41,42). Vesicles and over-expression of drug trans-
porters in immortalized cell lines are powerful tools as well to
evaluate such drug-transporter interactions, but often lack
human PTEC characteristics that could link drug-transporter
interactions to clinically relevant toxicological read-outs (43–
47). Human-derived immortalized renal cell models such as
human embryonic kidney 293 (HEK 293) and human kidney
2 (HK 2) cells have shown to be a valuable tool in screenings
in drug development, but have low or no endogenous
expression of relevant drug transporters (48,49). To overcome
these limitations, we have developed ciPTEC-OAT1 with
proven suitability for nephrotoxicity and drug-transporter
interactions studies (10–14). The broad range of drug
transporter expression in ciPTEC-OAT1 provides a strong
basis for highly predictive renal drug interaction studies. The
inter-complexity and overlap in substrates of renal drug
transporters, rather than through one drug transporter, is
incorporated because of this broad range of drug transporter
expression. This resembles a more physiological, in vivo-like,
mechanism of renal drug handling. Gene expression levels of
drug transporters in ciPTEC-OAT1 assessed here were lower
compared to levels observed in samples of the human renal
cortex, in accordance with other renal cell lines (48).
Functionality of OAT1, OCT2, BCRP, P-gp, and MRP2/4 in
ciPTEC in 2D cell culture has been demonstrated in multiple
studies (9,10,12–14).
Establishing highly predictive renal in vitro models for
nephrotoxicity and renal drug-transporter interactions could
reﬁne and, ultimately, replace animal experiments. Besides
the ethical issues, animal testing is expensive and not always
translatable because of species differences. Following this
study, future research should be directed to develop a method
that allows in vitro-in vivo extrapolation of data, using
experimental input from the 3D microﬂuidic PTEC model
in accordance with Kunze et al. (50). Such extrapolation
could demonstrate the added value and potential of our
model to replace current animal studies now used for renal
drug handling screenings.
Inﬂux drug transporters should be evaluated in parallel
to drug transporter efﬂux activity to obtain a reliable
prediction on renal excretion. Uptake via OCT2 and OAT1/
3 has been demonstrated in ciPTEC using uptake of
ﬂuorescent substrates (9,10). Using ciPTEC-OAT1,
transepithelial transport of the uremic toxins indoxyl sulfate
and kynurenic acid could be indirectly demonstrated when
cells were cultured on hollow ﬁber membranes, thereby
forming a renal epithelial tubule (13). Expanding the
platform with a third lane that includes a perfusable
basolateral compartment together with a perfusable apical
compartment in a 3D microﬂuidic platform could be used to
study transepithelial transport or organic cations and anion in
detail, as shown by Vormann et al. (under revision at AAPSJ)
Other potential applications for the three-compartmental
system are the incorporation of other segments of the renal
tubules or co-culture with vascular endothelial cells, as
recently was demonstrated (40,51).
In the current study, ﬂuorescent accumulation in the
chips was evaluated from ﬁve Z stacks with a 10-μm interval
per chip. This approach resulted in a variation of image focus
per chip and per experiment. To reduce variability per stack,
an image QC was introduced. We used a visually determina-
tion of in-focus and out-of-focus images. In our study, image
QC metrics tested, such as PLLS, resulted in low precision
and corresponding F scores because of overlapping means of
image QC metric between in-focus and out-of-focus images
assessed. Optimizing imaging in the OrganoPlate by using
autofocus could reduce the number of out-of-focus images
and improve image QC metric outcome. In addition, by
acquiring more Z-stacks per chip, chances of obtaining in-
focus images increase. A proper image QC is key in reliably
screening larger data sets typical for HT and should therefore
be optimized for each setting. Measuring ﬂuorescence inten-
sity in the entire image as compared to using thresholding
algorithms provided the most optimal semi-quantiﬁcation of
efﬂux activity. Corresponding Z′ scores where within an
acceptable range (0.5 >Z > 0) where standard deviation
bands of positive and negative controls were separated (27).
Aforementioned improvements in confocal imaging could
further increase separation of standard deviations from
controls.
CONCLUSION
To conclude, we present a 3D microﬂuidic PTEC model
including most important renal drug transporters in a
platform consisting of 96 chips. Multiplexing of different
endpoint read-outs in this platform and testing multiple
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conditions in one plate allows this platform to be suitable for
medium to high-throughput screenings and compatible with
most high-content imaging platforms.
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